Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Altimmune, Inc. stock logo
ALT
Altimmune
$6.92
-3.2%
$5.35
$3.55
$11.16
$561.26M0.582.89 million shs4.33 million shs
Structure Therapeutics Inc. stock logo
GPCR
Structure Therapeutics
$21.68
-2.4%
$22.64
$13.22
$49.91
$1.24B-1.87853,335 shs669,777 shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$818.56
+0.8%
$775.43
$677.09
$972.53
$775.78B0.413.66 million shs2.75 million shs
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$79.90
-1.4%
$67.30
$57.00
$148.15
$363.71B0.667.04 million shs7.47 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$24.51
-1.3%
$23.06
$20.92
$31.54
$139.52B0.5741.21 million shs46.35 million shs
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
$26.08
-8.7%
$26.46
$18.92
$81.73
$2.93B0.654.06 million shs6.08 million shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Altimmune, Inc. stock logo
ALT
Altimmune
0.00%+23.13%+19.72%+16.89%+8.46%
Structure Therapeutics Inc. stock logo
GPCR
Structure Therapeutics
0.00%+2.60%-11.26%+2.99%-58.31%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.00%+6.31%+11.76%+0.62%-5.74%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.00%+6.97%+20.94%+3.47%-44.24%
Pfizer Inc. stock logo
PFE
Pfizer
0.00%+4.93%+8.60%-4.76%-11.35%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
0.00%-6.29%-4.82%-15.57%-50.29%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Altimmune, Inc. stock logo
ALT
Altimmune
2.5178 of 5 stars
3.52.00.00.03.11.70.6
Structure Therapeutics Inc. stock logo
GPCR
Structure Therapeutics
2.2596 of 5 stars
3.52.00.00.02.21.70.6
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
4.8357 of 5 stars
3.43.03.34.03.41.71.9
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
4.6227 of 5 stars
4.13.02.50.02.20.04.4
Pfizer Inc. stock logo
PFE
Pfizer
4.9738 of 5 stars
3.34.04.24.32.81.73.1
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
4.3955 of 5 stars
4.51.00.04.72.23.30.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Altimmune, Inc. stock logo
ALT
Altimmune
3.00
Buy$20.20191.91% Upside
Structure Therapeutics Inc. stock logo
GPCR
Structure Therapeutics
3.00
Buy$76.50252.86% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.76
Moderate Buy$1,011.3723.55% Upside
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
2.27
Hold$112.0040.17% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.53
Moderate Buy$29.1718.99% Upside
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
3.00
Buy$87.15234.18% Upside

Current Analyst Ratings Breakdown

Latest PFE, NVO, LLY, VKTX, ALT, and GPCR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/5/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Erste Group Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
5/23/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/12/2025
Structure Therapeutics Inc. stock logo
GPCR
Structure Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$80.00 ➝ $75.00
5/2/2025
Structure Therapeutics Inc. stock logo
GPCR
Structure Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$60.00
5/2/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$1,100.00 ➝ $1,050.00
5/1/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight
5/1/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight
5/1/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
4/30/2025
Pfizer Inc. stock logo
PFE
Pfizer
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$24.00 ➝ $25.00
4/29/2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
4/28/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Reduce$1,150.00 ➝ $700.00
(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Altimmune, Inc. stock logo
ALT
Altimmune
$20K28,063.02N/AN/A$2.75 per share2.52
Structure Therapeutics Inc. stock logo
GPCR
Structure Therapeutics
N/AN/AN/AN/A$9.77 per shareN/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$49.00B15.83$13.34 per share61.34$15.05 per share54.39
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$303.14B1.18$3.70 per share21.57$4.64 per share17.22
Pfizer Inc. stock logo
PFE
Pfizer
$62.46B2.23$3.84 per share6.38$15.81 per share1.55
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/A$3.48 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Altimmune, Inc. stock logo
ALT
Altimmune
-$88.45M-$1.26N/AN/AN/A-199,076.92%-55.81%-50.60%8/6/2025 (Estimated)
Structure Therapeutics Inc. stock logo
GPCR
Structure Therapeutics
-$89.62M-$0.87N/AN/AN/AN/A-16.37%-15.68%8/6/2025 (Estimated)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$10.59B$12.2969.9026.301.4023.51%85.24%16.19%8/7/2025 (Estimated)
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$14.64B$3.3824.2917.150.9034.81%84.68%26.29%8/6/2025 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$8.03B$1.3817.388.090.6412.62%19.47%8.09%7/29/2025 (Estimated)
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$109.96M-$1.15N/AN/AN/AN/A-11.93%-11.57%7/23/2025 (Estimated)

Latest PFE, NVO, LLY, VKTX, ALT, and GPCR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Altimmune, Inc. stock logo
ALT
Altimmune
-$0.35-$0.26+$0.09-$0.26$0.00 million$0.01 million
5/8/2025Q1 2025
Structure Therapeutics Inc. stock logo
GPCR
Structure Therapeutics
-$0.24-$0.27-$0.03-$0.27N/AN/A
5/7/2025Q1 2025
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.92$0.92N/A$0.92N/A$11.87 billion
5/1/2025Q1 2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$4.64$3.34-$1.30$3.06$12.77 billion$12.73 billion
4/29/2025Q1 2025
Pfizer Inc. stock logo
PFE
Pfizer
$0.67$0.92+$0.25$0.52$14.43 billion$13.72 billion
4/23/2025Q1 2025
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
-$0.31-$0.41-$0.10-$0.41N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Altimmune, Inc. stock logo
ALT
Altimmune
N/AN/AN/AN/AN/A
Structure Therapeutics Inc. stock logo
GPCR
Structure Therapeutics
N/AN/AN/AN/AN/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.000.73%N/A48.82%11 Years
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$1.632.04%N/A48.22%N/A
Pfizer Inc. stock logo
PFE
Pfizer
$1.727.02%N/A124.64%16 Years
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/AN/AN/AN/AN/A

Latest PFE, NVO, LLY, VKTX, ALT, and GPCR Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/23/2025
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.437.69%5/9/20255/9/20256/13/2025
5/5/2025
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.500.73%5/16/20255/16/20256/10/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Altimmune, Inc. stock logo
ALT
Altimmune
N/A
16.87
16.87
Structure Therapeutics Inc. stock logo
GPCR
Structure Therapeutics
N/A
27.63
27.63
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.00
1.15
0.97
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.62
0.74
0.55
Pfizer Inc. stock logo
PFE
Pfizer
0.63
1.00
0.73
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
N/A
36.47
36.47

Institutional Ownership

CompanyInstitutional Ownership
Altimmune, Inc. stock logo
ALT
Altimmune
78.05%
Structure Therapeutics Inc. stock logo
GPCR
Structure Therapeutics
91.78%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
11.54%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
76.03%
CompanyEmployeesShares OutstandingFree FloatOptionable
Altimmune, Inc. stock logo
ALT
Altimmune
5081.11 million68.21 millionOptionable
Structure Therapeutics Inc. stock logo
GPCR
Structure Therapeutics
13657.34 million51.86 millionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
39,000947.74 million948.08 millionOptionable
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
54,4004.49 billion4.48 billionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
83,0005.69 billion5.66 billionOptionable
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
20112.31 million106.20 millionOptionable

Recent News About These Companies

Viking Therapeutics (VKTX) Rises on Expected Developments
Brokers Issue Forecasts for VKTX FY2026 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Altimmune stock logo

Altimmune NASDAQ:ALT

$6.92 -0.23 (-3.22%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$6.96 +0.04 (+0.65%)
As of 06/13/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Structure Therapeutics stock logo

Structure Therapeutics NASDAQ:GPCR

$21.68 -0.54 (-2.43%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$21.70 +0.02 (+0.07%)
As of 06/13/2025 05:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$818.56 +6.53 (+0.80%)
Closing price 06/13/2025 03:59 PM Eastern
Extended Trading
$819.12 +0.56 (+0.07%)
As of 06/13/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Novo Nordisk A/S stock logo

Novo Nordisk A/S NYSE:NVO

$79.90 -1.15 (-1.42%)
Closing price 06/13/2025 03:59 PM Eastern
Extended Trading
$80.01 +0.11 (+0.14%)
As of 06/13/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Pfizer stock logo

Pfizer NYSE:PFE

$24.51 -0.33 (-1.32%)
Closing price 06/13/2025 03:59 PM Eastern
Extended Trading
$24.52 +0.01 (+0.06%)
As of 06/13/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Viking Therapeutics stock logo

Viking Therapeutics NASDAQ:VKTX

$26.08 -2.50 (-8.75%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$26.22 +0.14 (+0.54%)
As of 06/13/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.